COVID-19-Associated Pulmonary Aspergillosis in a Patient Treated With Remdesivir, Dexamethasone, and Baricitinib: A Case Report

Remdesivir, dexamethasone, and baricitinib have recently been used to treat patients with coronavirus disease 2019 (COVID-19) and respiratory failure. However, the adverse effects of combination therapy have not been fully explored. A 64-year-old man was diagnosed with COVID-19 and was treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimada, Ayako, Ohnaka, Shinnosuke, Kubo, Kosumi, Nakashima, Masanao, Nagai, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Radiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064704/
https://www.ncbi.nlm.nih.gov/pubmed/35518522
http://dx.doi.org/10.7759/cureus.23755
Descripción
Sumario:Remdesivir, dexamethasone, and baricitinib have recently been used to treat patients with coronavirus disease 2019 (COVID-19) and respiratory failure. However, the adverse effects of combination therapy have not been fully explored. A 64-year-old man was diagnosed with COVID-19 and was treated with remdesivir, dexamethasone, and baricitinib. His respiratory condition worsened on day 17, and in the following days, he was diagnosed with pneumomediastinum and COVID-19-associated pulmonary aspergillosis (CAPA). His condition improved with a reduction in the corticosteroid regime and antifungal treatment. This is the first case of pulmonary aspergillosis in a patient with COVID-19 that was treated with remdesivir, dexamethasone, and baricitinib.

Ejemplares similares